Oncology Institute (NASDAQ:TOI) Upgraded at B. Riley

B. Riley upgraded shares of Oncology Institute (NASDAQ:TOI) to a strong-buy rating in a report released on Tuesday morning,Zacks.com reports.

Separately, BTIG Research assumed coverage on shares of Oncology Institute in a research note on Thursday, May 15th. They issued a “buy” rating and a $7.00 price target on the stock.

Oncology Institute Stock Performance

Shares of NASDAQ TOI opened at $3.65 on Tuesday. The stock has a fifty day moving average price of $2.73 and a two-hundred day moving average price of $1.73. The company has a debt-to-equity ratio of 14.58, a quick ratio of 1.59 and a current ratio of 1.79. The firm has a market cap of $325.69 million, a P/E ratio of -5.21 and a beta of 0.02. Oncology Institute has a 1 year low of $0.13 and a 1 year high of $3.77.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter. Oncology Institute had a negative net margin of 15.38% and a negative return on equity of 445.02%. The company had revenue of $104.41 million for the quarter.

Insider Buying and Selling

In other news, Director Growth I. L.P. M33 sold 76,324 shares of Oncology Institute stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $3.05, for a total transaction of $232,788.20. Following the transaction, the director directly owned 1,272,724 shares of the company’s stock, valued at $3,881,808.20. This trade represents a 5.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Brad Hively sold 1,976,137 shares of Oncology Institute stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total transaction of $5,671,513.19. Following the transaction, the director directly owned 603,501 shares in the company, valued at approximately $1,732,047.87. This represents a 76.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 4,726,137 shares of company stock valued at $13,379,013. 8.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oncology Institute

Institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC lifted its position in Oncology Institute by 613.6% in the 4th quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after acquiring an additional 109,769 shares in the last quarter. Virtu Financial LLC acquired a new stake in Oncology Institute in the 4th quarter valued at $41,000. Renaissance Technologies LLC increased its stake in Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock valued at $56,000 after buying an additional 12,000 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Oncology Institute in the 1st quarter valued at $131,000. Finally, Josh Arnold Investment Consultant LLC acquired a new stake in Oncology Institute in the 1st quarter valued at $2,267,000. 36.86% of the stock is owned by institutional investors.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.